eGenesis Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026
CAMBRIDGE, Mass.--( BUSINESS WIRE)-- eGenesis, a biotechnology company developing human-compatible engineered organs to address the global organ shortage, is proud to have been named to Fast Company’s prestigious list of the World’s Most Innovative Companies of 2026.
The company was named No. 1 in the Biotech category and ranked No. 34 on Fast Company’s 2026 World’s 50 Most Innovative Companies list.
This year’s list shines a spotlight on businesses that are shaping industry and culture through their innovations. Alongside the World’s 50 Most Innovative Companies, Fast Company recognizes 720 honorees across 59 sectors and regions.
“Being named the No. 1 biotech company by Fast Company is a powerful validation of our mission to solve one of medicine’s most urgent challenges, the global organ shortage,” said Mike Curtis, Ph.D, CEO, eGenesis. “We are at an inflection point, with FDA clearance to begin clinical trials for our kidney and liver programs, leveraging the growing body of clinical evidence demonstrating the potential of engineered porcine organs to transform patients’ lives. This recognition reflects the dedication of our team and the patients who continue to inspire our work every day.”
eGenesis is advancing the field of xenotransplantation through its proprietary genome engineering platform, designed to produce the safest porcine organs to enable long-term function in human patients. The company recently received FDA clearance for a Phase 1/2/3 clinical trial of EGEN-2784, its engineered porcine kidney, in patients with end-stage kidney disease. This progression is supported by landmark clinical data showing a record nine months of dialysis independence with a genetically engineered porcine-derived kidney, demonstrating the potential durability and real-world impact of the Company’s products. In addition, the FDA has approved the first clinical trial of EGEN-5784, a porcine liver designed to provide perfusion support to patients suffering from liver failure, being developed in collaboration with Terumo/OrganOx.
The World’s Most Innovative Companies is Fast Company’s hallmark franchise and one of its most anticipated editorial efforts of the year. To determine honorees, Fast Company’s editors and writers review companies driving progress around the world and across industries, evaluating thousands of submissions through a competitive application process. The result is a globe-spanning guide to innovation today, from early-stage startups to some of the most valuable companies in the world.
“Our list of the Most Innovative Companies is about spotlighting organizations that don’t just adapt to change—they drive it,” said Brendan Vaughan, editor-in-chief of Fast Company. “The companies we honor this year are redefining what leadership looks like in 2026, pairing bold ideas with measurable impact and turning breakthrough innovation into real-world value. They are setting the pace for their industries and offering a blueprint for what sustained innovation can achieve.”
The full list of Fast Company’s Most Innovative Companies honorees can now be found at fastcompany.com. It will also be available on newsstands beginning March 31, 2026.
About eGenesis
eGenesis is a clinical-stage biotechnology company developing human-compatible engineered organs to address the severe global organ shortage. The Company’s proprietary genome engineering platform uniquely addresses cross-species molecular incompatibilities and viral risk to improve outcomes for patients suffering from organ failure. eGenesis is advancing programs in kidney transplantation, liver failure, and heart transplantation. For more information, visit www.egenesisbio.com.